Reversibility of Male Factor Infertility: Mechanisms and Evidence from the Literature
- 1Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Abstract
Male factor infertility contributes to approximately 50% of reproductive failure in couples worldwide. We conducted a narrative critical review synthesizing evidence from systematic reviews, meta-analyses, randomized controlled trials, and clinical practice guidelines on reversible and irreversible causes of male infertility, examining hormonal, surgical, pharmacological, lifestyle, and drug-induced etiologies. The majority of identifiable etiologies demonstrate some degree of reversibility. Varicocele (prevalence 25–40% in infertile men) achieves natural pregnancy rates of 30–40% after varicocelectomy. Hypogonadotropic hypogonadism responds to gonadotropin therapy with spermatogenesis induction in 90–95% of cases. Obstructive azoospermia achieves ductal patency rates of 85–97% with microsurgical reconstruction. Male accessory gland inflammation is reversible with prompt antibiotic therapy. Spermiotoxic drug exposures—including anabolic-androgenic steroids, sulfasalazine, and chemotherapy—show variable reversibility depending on agent and duration of exposure. Normogonadotropic normotestosteronemic oligozoospermia represents a commonly encountered phenotype that may respond to empirical medical therapy. Lifestyle modifications demonstrate measurable benefits in selected patients. Irreversible causes include Klinefelter syndrome, Y-chromosome AZFa/b microdeletions, and severe post-chemotherapy damage. Systematic andrological evaluation, including comprehensive drug history, is essential to identify treatable causes and guide clinical management.
Related
- Endometriosis-Associated Infertility: Molecular Mechanisms and Evidence-Based Clinical Management
- Inflammation–fibrosis crosstalk in endometriosis: immune–stromal mechanisms linking lesion persistence to pain and infertility
- Alcohol and male infertility: is there a safe dose? Evidence of accessory gland dysfunction, oxidative stress, and sperm DNA damage
- Diagnostic approaches for tubal factor infertility: a systematic review of HSG, HyCoSy, HyFoSy, and laparoscopy.
- Microfluidic sperm separation for intracytoplasmic sperm injection yields similar blastocyst rates compared with density gradient, however, may be of benefit for male factor infertility: a randomized sibling oocyte study.
BibTeX
@article{vignera2026reversibility,
title = {{Reversibility of Male Factor Infertility: Mechanisms and Evidence from the Literature}},
author = {Sandro La Vignera and Aldo E. Calogero and Rossella Cannarella and Andrea Crafa and Federica Barbagallo and Rosita A. Condorelli},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27208968},
url = {https://www.mdpi.com/1422-0067/27/20/8968},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Reversibility of Male Factor Infertility: Mechanisms and Evidence from the Literature
AU - Sandro La Vignera
AU - Aldo E. Calogero
AU - Rossella Cannarella
AU - Andrea Crafa
AU - Federica Barbagallo
AU - Rosita A. Condorelli
PY - 2026
DA - 2026/10/09
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27208968
UR - https://www.mdpi.com/1422-0067/27/20/8968
AB - Male factor infertility contributes to approximately 50% of reproductive failure in couples worldwide. We conducted a narrative critical review synthesizing evidence from systematic reviews, meta-analyses, randomized controlled trials, and clinical practice guidelines on reversible and irreversible causes of male infertility, examining hormonal, surgical, pharmacological, lifestyle, and drug-induced etiologies. The majority of identifiable etiologies demonstrate some degree of reversibility. Varicocele (prevalence 25–40% in infertile men) achieves natural pregnancy rates of 30–40% after varicocelectomy. Hypogonadotropic hypogonadism responds to gonadotropin therapy with spermatogenesis induction in 90–95% of cases. Obstructive azoospermia achieves ductal patency rates of 85–97% with microsurgical reconstruction. Male accessory gland inflammation is reversible with prompt antibiotic therapy. Spermiotoxic drug exposures—including anabolic-androgenic steroids, sulfasalazine, and chemotherapy—show variable reversibility depending on agent and duration of exposure. Normogonadotropic normotestosteronemic oligozoospermia represents a commonly encountered phenotype that may respond to empirical medical therapy. Lifestyle modifications demonstrate measurable benefits in selected patients. Irreversible causes include Klinefelter syndrome, Y-chromosome AZFa/b microdeletions, and severe post-chemotherapy damage. Systematic andrological evaluation, including comprehensive drug history, is essential to identify treatable causes and guide clinical management.
SN - 1422-0067
ER -